Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice
Frontiers in Pharmacology · 30.04.2025 · 16
DOI: 10.3389/fphar.2025.1572906 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.04.2025. Verfasst von Rui Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yaan People's Hospital, Yaan, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Resveratrol, a naturally occurring polyphenolic compound found in grapes, berries, and traditional medicinal plants like Polygonum cuspidatum, has been used for centuries in traditional medicine systems for its anti-inflammatory, antioxidant, and cardioprotective properties. Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by intestinal barrier disruption due to excessive colonocyte apoptosis, leading to increased permeability and inflammation. Targeting apoptosis is a critical therapeutic strategy for UC. Aim of the study This study aims to investigate the therapeutic potential of Resveratrol in ulcerative colitis (UC) by targeting excessive colonocyte apoptosis and intestinal barrier dysfunction. Specifically, we seek to elucidate the mechanisms through which Resveratrol modulates apoptosis-related pathways and evaluate its efficacy in restoring intestinal homeostasis and mitigating UC progression in both in vivo and in vitro models. Materials and Methods We used dextran sulfate sodium (DSS) to induce UC in a mouse model. Colonic damage was assessed through colonic length measurement, histological examination, and immunofluorescence staining. Single-cell sequencing was employed to explore changes in the colonic immune microenvironment and cellular signaling pathways after Resveratrol treatment. In vitro , colonocytes isolated from healthy mouse colonic tissue were exposed to TGF-β to induce apoptosis. DNA fragmentation, mitochondrial membrane potential, and annexin V/propidium iodide staining were used to assess apoptosis. Additionally, we employed an Adeno-Associated Virus system to overexpress MDM2 in the colon and evaluate its protective role in DSS-induced UC.
Results
Resveratrol treatment effectively repaired colonic damage in the UC mouse model by significantly increasing colon length, reducing inflammatory cell infiltration, and mitigating mucosal injury. Single-cell sequencing revealed that Resveratrol primarily targeted colonocytes, decreasing genes related to apoptosis and the P53 pathway. In vitro , Resveratrol reduced DNA fragmentation, apoptotic cell populations, and increased mitochondrial membrane potential in a dose-dependent manner. Furthermore, Resveratrol increased MDM2 expression, inhibiting P53 and downstream pro-apoptotic signaling. Nutlin-3a, an MDM2 inhibitor, reversed the anti-apoptotic effects of Resveratrol. Overexpression of MDM2 in the colon protected against DSS-induced damage.
Conclusion
Resveratrol is an effective treatment for DSS-induced UC, primarily by inhibiting excessive apoptosis in colonocytes through the MDM2/P53/PUMA axis. MDM2 presents a promising therapeutic target for UC treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Yaan People's Hospital, Yaan, China.
- School of Basic Medical Sciences, Southwest Medical University, Luzhou, China.
- Department of Anesthesiology Management, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing, China.
- Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, China.
- Department of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Zitieren
APA
Tang, R., Jiang, L., Ji, Q., Kang, P., Liu, Y., Miao, P., Xu, X., & Tang, M. (2025). Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1572906
Vancouver
Tang R, Jiang L, Ji Q, Kang P, Liu Y, Miao P, et al. Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1572906
BibTeX
@article{Tang2025,
author = {Tang, Rui and Jiang, Ling and Ji, Quan and Kang, Pengyuan and Liu, Yuan and Miao, Pengyu and Xu, Xiaofan and Tang, Mingxi},
title = {Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1572906}
}
EUVIMED